Pneumococcal disease is an infection caused by bacteria called Streptococcus pneumoniae (also known as pneumococcus). It causes contagious and potentially severe illness, including pneumonia, meningitis and sepsis, so early diagnosis and treatment is important. Vaccines have been the best protection against developing infection. The purpose of this study is to measure whether an investigational pneumococcal vaccine is safe and can help the body to develop germ-fighting agents called “antibodies” (immunogenicity)  for adults 50 years of age and older.

The potential benefits to participants would be study-related medical care at no-cost and compensation for study related efforts and travel. On a wider scale, there may be general benefits to society because the investigational treatment may become a future treatment option.

To qualify for the study, you must be:

• Aged 50 years or older on the day of inclusion.
• Has received a previous pneumococcal vaccination.
• Has not had a previous  invasive pneumococcal disease.
• Other criteria may apply*

*There are multiple studies available to participate in and each may require different criteria to be approved as a participant.

To learn more about this trial and to find out if you qualify, please call 402.934.0044 or complete the form on our Contact page.